This has been evidenced by the decrease in fasting insulin levels observed in women with PCOS that undergo insulin-sensitizing pharmacotherapy, which appears to concurrently lower androgenemia and improve ovarian functionalism [65]. This evidence concerns the gene INS and polycystic ovary syndrome.